Why ImmunityBio, Inc. (IBRX) Stock Rose 6.9% on Sep 30, 2026
What happened
ImmunityBio shares surged 9.74% to $9.69 on September 30, 2026, driven by a technical breakout above resistance and growing optimism around its cancer immunotherapy pipeline, according to the ImmunityBio News Hub cited by Yahoo Finance. Volume spiked to 20.3M shares — 2.50x the time-adjusted daily average — reflecting elevated institutional and retail interest tied to the company's $5.8B addressable market opportunity and chairman Patrick Soon-Shiong's broader cancer-immunotherapy initiatives.
ImmunityBio earnings release on November 3, 2026 (consensus EPS estimate: −$0.08); clinical milestones for Anktiva adoption and any international regulatory developments.
Frequently asked questions
Why did ImmunityBio, Inc. (IBRX) stock rise on Sep 30, 2026?
ImmunityBio shares surged 9.74% to $9.69 on September 30, 2026, driven by a technical breakout above resistance and growing optimism around its cancer immunotherapy pipeline, according to the ImmunityBio News Hub cited by Yahoo Finance. Volume spiked to 20.3M shares — 2.50x the time-adjusted daily average — reflecting elevated institutional and retail interest tied to the company's $5.8B addressable market opportunity and chairman Patrick Soon-Shiong's broader cancer-immunotherapy initiatives.
How much did IBRX stock rise on Sep 30, 2026?
IBRX rose 6.9% during the Sep 30, 2026 trading session.